Samsung Bioepis Signs Exclusive Brazilian Supply Deal
Samsung Episholdings disclosed on Oct. 21 that its subsidiary Samsung Bioepis signed an exclusive supply contract for “SB12” through the Productive Development Partnership (PDP) project led by the Brazilian government.SB12 is a biosimilar to “Soliris (eculizumab)," a rare disease treatment developed
Samsung Bioepis, a subsidiary of Samsung Electronics, has signed an exclusive supply deal for "SB12", a biosimilar to the rare disease treatment "Soliris (eculizumab)" developed by U.S.-based Alexion, through Brazil's Productive Development Partnership (PDP) project. Eculizumab, a monoclonal antibody that inhibits complement protein C5, is used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria (PNH).
The exclusive supply agreement is part of the PDP program, a public-private cooperation initiative promoted by the Brazilian government to stabilize pharmaceutical supply and enhance local manufacturing capabilities. Samsung Bioepis intends to sign more supply contracts in the future to fulfill the agreement, but specific supply volume and unit price details have yet to be finalized.
The company stated that it will provide further disclosure when additional information becomes available, either upon signing subsequent supply contracts or within one month.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
